KMC Speciality (524520)
Fast GrowerFairStock Score: 46/100 — MIXED
Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹81.32 |
| Market Cap | ₹1,333.88 Cr |
| P/E Ratio | 38.15 |
| ROCE | 17.37% |
| ROE | 23.96% |
| Dividend Yield | 0% |
| Profit Growth | 82.82% |
| Debt/Equity | — |
| Sales Growth | 33.74% |
| 52-Week Range | ₹68.26 — ₹97.6 |
| Sector | Healthcare Services |
| Book Value | ₹9.69 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
Let me look at KMC Speciality the way I look at any business—through numbers, not noise. The company earns a return on equity of 23.96% and a ROCE of 17.37%, so it is converting capital into profits efficiently. Book value is only ₹9.69, yet the market pays ₹81.32, a price-to-book of 8.39; that is a rich price, but quality often demands a premium. Sales grew 33.74% and profits jumped 82.82%, and the Piotroski F-Score of 7/9 suggests the earnings quality is backed by solid fundamentals. On the surface, a P/E of 38.15 looks expensive, but the PEG ratio of 0.65 tells me the growth is doing a lot of the heavy lifting. I won't overpay for momentum; I need the growth to continue. The latest quarter shows sales of ₹82 crore and net profit of ₹14 crore, so the engine is still running. Still, I have reservations. There is no dividend—zero yield—so my return wholly depends on reinvestment and eventual valuation. Promoter holding is not disclosed in the data I have; I cannot judge whether the people running the shop have enough skin in the game. Debt-to-equity is also not available, leaving a gap in my safety check. FairStock Score of 43/100 is mixed; the market is paying for a wonderful business, but I must ask whether it is a wonderful price. If growth moderates, a high P/E leaves little margin of safety. I would keep it on my watch list, not my buy list, unless the price falls or earnings catch up with optimism.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer